Have a personal or library account? Click to login
Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system Cover

Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system

Acta Pharmaceutica
AHEAD OF PRINT
By: Zhu Wang,  Guoping Gan and  Haiping Yao  
Open Access
|Dec 2025

Authors

Zhu Wang

Department of Pediatrics, The First College of Clinical Medical Science China Three Gorges University & Yichang Central People’s Hospital, Yichang, P. R. China

Guoping Gan

College of Pharmacy, Hubei University of Chinese Medicine, Wuhan, P. R. China

Haiping Yao

yaohaiping@ctgu.edu.cn

Department of Pharmacy, The First College of Clinical Medical Science China Three Gorges University & Yichang Central People’s Hospital, Yichang, P. R. China
College of Pharmacy, Hubei University of Chinese Medicine, Wuhan, P. R. China
DOI: https://doi.org/10.2478/acph-2026-0001 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Accepted on: Nov 24, 2025
Published on: Dec 17, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
tigecycline,
omadacycline,
eravacycline,
pharmaco-vigilance,
gastrointestinal safety,
FAERS
Related subjects:
Pharmacy,
Pharmacy, other

© 2025 Zhu Wang, Guoping Gan, Haiping Yao, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT